|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0030705,
umls-concept:C0040808,
umls-concept:C0220825,
umls-concept:C0332293,
umls-concept:C0334634,
umls-concept:C0376622,
umls-concept:C0392760,
umls-concept:C0580822,
umls-concept:C1332002,
umls-concept:C1336767,
umls-concept:C1547300,
umls-concept:C1548760,
umls-concept:C1550594,
umls-concept:C1704939,
umls-concept:C1823242
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-8-16
|
|
pubmed:abstractText |
The genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of other indolent lymphoproliferative disorders, Topoisomerase IIalpha, glutathione-s-transferasepi (GSTpi) and ABCG2 (BCRP) chemoresistance genes being over-expressed in MCL. In our study, expression levels of the above mentioned genes plus MDR1 were tested on bone marrow samples from 20 patients treated with Rituximab plus hyper-CVAD regimen, in order to evaluate a possible impact of the chemoresistance phenomenon on this promising treatment regimen. All patients expressed ABCG2 and MDR1 genes; 85% of cases expressed GSTpi and topoisomerase IIalpha. Only ABCG2 were over-expressed in comparison both with marrow from healthy donors and tonsilar CD5+/CD20+ lymphocytes (adopted as normal counterpart of the neoplastic population). The overall response rate of the entire series was 87.5%, with 44% of complete responses. Fifty-seven percent of patients achieved the clearance of minimal residual disease. Levels of tested genes did not condition either quality of clinical response or PFS (76% at 24 months). Nevertheless, an ABCG2 higher expression appeared associated with a worse PFS and levels of this gene paralleled the status of minimal residual disease. A further evaluation of ABCG2 expression in larger series of MCL patients would be suitable.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ABCB1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/ABCG2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/ATP-Binding Cassette Transporters,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type II,
http://linkedlifedata.com/resource/pubmed/chemical/DNA topoisomerase II alpha,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/GSTP1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Glutathione S-Transferase pi,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1042-8194
|
|
pubmed:author |
pubmed-author:BenedettiEdoardoE,
pubmed-author:BrizziStefaniaS,
pubmed-author:CanestraroMartinaM,
pubmed-author:CaraccioloFrancescoF,
pubmed-author:CiabattiElenaE,
pubmed-author:FazziRitaR,
pubmed-author:GalimbertiSaraS,
pubmed-author:GuerriniFrancescaF,
pubmed-author:NagyBalintB,
pubmed-author:PaciniSimoneS,
pubmed-author:PapineschiFedericoF,
pubmed-author:PetriniMarioM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1502-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17701580-ATP-Binding Cassette Transporters,
pubmed-meshheading:17701580-Adult,
pubmed-meshheading:17701580-Aged,
pubmed-meshheading:17701580-Antibodies, Monoclonal,
pubmed-meshheading:17701580-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:17701580-Antigens, Neoplasm,
pubmed-meshheading:17701580-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17701580-Case-Control Studies,
pubmed-meshheading:17701580-Cyclophosphamide,
pubmed-meshheading:17701580-DNA Topoisomerases, Type II,
pubmed-meshheading:17701580-DNA-Binding Proteins,
pubmed-meshheading:17701580-Dexamethasone,
pubmed-meshheading:17701580-Doxorubicin,
pubmed-meshheading:17701580-Drug Resistance, Multiple,
pubmed-meshheading:17701580-Drug Resistance, Neoplasm,
pubmed-meshheading:17701580-Female,
pubmed-meshheading:17701580-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17701580-Glutathione S-Transferase pi,
pubmed-meshheading:17701580-Humans,
pubmed-meshheading:17701580-Lymphoma, Mantle-Cell,
pubmed-meshheading:17701580-Male,
pubmed-meshheading:17701580-Middle Aged,
pubmed-meshheading:17701580-Neoplasm Proteins,
pubmed-meshheading:17701580-P-Glycoprotein,
pubmed-meshheading:17701580-Prognosis,
pubmed-meshheading:17701580-Survival Rate,
pubmed-meshheading:17701580-Treatment Outcome,
pubmed-meshheading:17701580-Tumor Markers, Biological,
pubmed-meshheading:17701580-Vincristine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.
|
|
pubmed:affiliation |
Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy. s.galimberti@med.unipi.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Clinical Trial, Phase II
|
